Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

1.

Stroke and bleeding risk in atrial fibrillation.

Senoo K, Lane D, Lip GY.

Korean Circ J. 2014 Sep;44(5):281-90. doi: 10.4070/kcj.2014.44.5.281. Review.

2.

Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.

Ng KH, Hart RG, Eikelboom JW.

Cardiol Ther. 2013 Dec;2(2):135-49. doi: 10.1007/s40119-013-0019-y. Epub 2013 Aug 6.

3.

Continuation of dabigatran therapy in "real-world" practice in Hong Kong.

Ho MH, Ho CW, Cheung E, Chan PH, Hai JJ, Chan KH, Chan EW, Leung GK, Tse HF, Siu CW.

PLoS One. 2014 Aug 1;9(8):e101245. doi: 10.1371/journal.pone.0101245. eCollection 2014.

4.

Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation.

Uhm JS, Won H, Joung B, Nam GB, Choi KJ, Lee MH, Kim YH, Pak HN.

Yonsei Med J. 2014 Sep;55(5):1238-45. doi: 10.3349/ymj.2014.55.5.1238.

5.

A case of rivaroxaban associated intracranial hemorrhage.

Lo JC, Gerona RR.

West J Emerg Med. 2014 Jul;15(4):375-7. doi: 10.5811/westjem.2014.2.19440.

6.

Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review.

Manatsathit W, Al-Hamid H, Leelasinjaroen P, Hashmi U, McCullough PA.

Cardiovasc Diagn Ther. 2014 Jun;4(3):224-31. doi: 10.3978/j.issn.2223-3652.2014.03.07.

7.

Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study.

Arshad A, Johnson CK, Mittal S, Buch E, Hamam I, Tran T, Shaw RE, Musat D, Preminger M, Sichrovsky T, Herweg B, Shivkumar K, Hummel J, Steinberg JS.

Pacing Clin Electrophysiol. 2014 Jun;37(6):665-73. doi: 10.1111/pace.12401. Epub 2014 May 4.

8.

Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.

Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, Becker RC, Breithardt G, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Investigators.

J Am Heart Assoc. 2014 Apr 22;3(2):e000521. doi: 10.1161/JAHA.113.000521.

9.

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerations.

Ahrens I, Bode C.

J Blood Med. 2014 Feb 24;5:25-30. doi: 10.2147/JBM.S32957. eCollection 2014. Review.

10.

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.

Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L.

Eur Heart J. 2014 Jul 21;35(28):1864-72. doi: 10.1093/eurheartj/ehu046. Epub 2014 Feb 20.

11.

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.

Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Lip GY.

Eur Heart J. 2014 Jul 21;35(28):1897-906. doi: 10.1093/eurheartj/ehu006. Epub 2014 Feb 9.

12.

Complete circumferential rectal ulceration and haemorrhage secondary to the use of a faecal management system.

Shaker H, Maile EJ, Telford KJ.

Therap Adv Gastroenterol. 2014 Jan;7(1):51-5. doi: 10.1177/1756283X13501947.

13.

Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).

Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KA, Califf RM; ROCKET AF Investigators.

J Am Coll Cardiol. 2014 Mar 11;63(9):891-900. doi: 10.1016/j.jacc.2013.11.013. Epub 2013 Dec 4.

14.

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.

J Am Heart Assoc. 2013 Nov 25;2(6):e000535. doi: 10.1161/JAHA.113.000535.

15.

New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons.

Sardar P, Chatterjee S, Wu WC, Lichstein E, Ghosh J, Aikat S, Mukherjee D.

PLoS One. 2013 Oct 25;8(10):e77694. doi: 10.1371/journal.pone.0077694. eCollection 2013.

16.

Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study.

Pastori D, Carnevale R, Cangemi R, Saliola M, Nocella C, Bartimoccia S, Vicario T, Farcomeni A, Violi F, Pignatelli P.

J Am Heart Assoc. 2013 Oct 28;2(6):e000364. doi: 10.1161/JAHA.113.000364.

17.
18.

Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry?

Chiong JR, Cheung RJ.

Korean Circ J. 2013 May;43(5):287-92. doi: 10.4070/kcj.2013.43.5.287.

19.

Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature.

Martins MA, Reis AM, Sales MF, Nobre V, Ribeiro DD, Rocha MO, Ribeiro AL.

BMC Pharmacol Toxicol. 2013 May 4;14:27. doi: 10.1186/2050-6511-14-27. Review.

20.

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

Harris K, Mant J.

Int J Clin Pract. 2013 Jul;67(7):647-55. doi: 10.1111/ijcp.12177. Epub 2013 Apr 28. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk